Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Currently, the potential risk of atrial fibrillation associated with antihyperglycemic drug use has been a topic of considerable interest. However, it remains uncertain whether different classes of antihyperglycemic drug therapy are associated with the risk of atrial fibrillation risk. Here, we investigated the association between different classes of antihyperglycemic drugs and new-onset atrial fibrillation (NAF). A case-matched study was performed based on the National Health Insurance Program in Taiwan. Patients who had NAF were considered the NAF group and were matched in a 1:4 ratio with patients without NAF, who were assigned to the non-NAF group. Patients were matched according to sex, age, diabetes mellitus duration, index date, and Charlson Comorbidity Index score. We used multivariate logistic regression controlling for potential confounders to examine the association between different classes of antihyperglycemic drug use and the risk of NAF. Overall, we identified 2,882 cases and 11,528 matched controls for the study. After adjusting for sex, age, comorbidities, and concurrent medications, users of biguanides or thiazolidinediones were at a lower risk of developing NAF when compared with non-users (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.71-0.95 and OR 0.72, 95% CI 0.63-0.83, respectively). In contrast, users of insulin were at a higher risk of developing NAF than were non-users (OR 1.19, 95% CI 1.06-1.35). Sulfonylureas, glinides, α-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were not associated with developing the risk of NAF. In conclusion, the use of biguanides or thiazolidinediones may be associated with a low risk of NAF, whereas insulin may be associated with a significant increase in the risk of NAF in patients with type 2 diabetes mellitus during long-term follow-up. Further prospective randomized studies should investigate which specific class of antihyperglycemic drug treatment for diabetes mellitus can prevent or postpone NAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the EMPA-REG OUTCOME trial, empagliflozin, compared with placebo, reduced CV death or HF hospitalization consistently in patients with diabetes with or without AF (P int = 0.56).604”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [604]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273
Wu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T. (2012) · JAMA · doi:10.1001/2012.jama.11975 · Cited by 818
Piccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J., & Curtis, L. H. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962688 · Cited by 565
Huxley, R. R., Filion, K. B., Konety, S., & Alonso, A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.004 · Cited by 561
Recent advances in the molecular pathophysiology of atrial fibrillation
Wakili, R., Voigt, N., Kääb, S., Dobrev, D., & Nattel, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46315 · Cited by 545
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.540480 · Cited by 420
Conen, D. (2011) · JAMA · doi:10.1001/jama.2011.659 · Cited by 345
Diabetes mellitus, glycemic control, and risk of atrial fibrillation
Dublin, S., Glazer, N. L., Smith, N. L., Psaty, B. M., Lumley, T., Wiggins, K. L., Page, R. L., & Heckbert, S. R. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1340-y · Cited by 310
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Atrial Fibrillation and Diabetes Mellitus
Wang, A., Green, J. B., Halperin, J. L., & Piccini, J. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.020 · Cited by 400
Batta, A., Hatwal, J., Batta, A., Verma, S., & Sharma, Y. P. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i5.229 · Cited by 126
Chen, H.-Y., Huang, J., Siao, W.-Z., & Jong, G. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01048-x · Cited by 109
Self-citationMetabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
Bode, D., Pronto, J. R. D., Schiattarella, G. G., & Voigt, N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01038-6 · Cited by 111
“Strikingly, in a retrospective case–control study, patients treated with insulin were at higher risk of developing AF than patients who were not receiving insulin 30 .”
Heart failure with preserved ejection fraction based on aging and comorbidities
Lin, Y. H., Fu, S., Yao, Y., Li, Y., Zhao, Y., & Luo, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02935-x · Cited by 85
“Metformin reduces proinflammatory adipokines and has anti-inflammatory roles [128, 129].”
BackgroundPacker, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1646 · Cited by 62
Packer, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
Qin, Z., Wang, W. J., Liao, D., Wu, X., & Li, X. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123984 · Cited by 64
Ostropolets, A., Elias, P. A., Reyes, M. V., Wan, E. Y., Pajvani, U. B., Hripcsak, G. M., & Morrow, J. (2021) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.120.009115 · Cited by 60
Packer, M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0927-9 · Cited by 52
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation
Papazoglou, Α. S., Κάρτας, Α., Moysidis, D. V., Tsagkaris, C., Papadakos, S. P., Bekiaridou, Α., Samaras, A., Karagiannidis, E., Papadakis, M., & Giannakoulas, G. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01473-0 · Cited by 59
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 51
“found no association between AF development and the use of sulfonylureas in diabetic subjects [111].”
BackgroundInfluentialChan, Y., Chao, T., Chen, S., Lee, H., Li, P., Chen, W.-M., Yeh, Y., Kuo, C.-T., See, L., & Lip, G. Y. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01549-x · Cited by 50
“Indeed, insulin use may also be associated with an increased risk of AF [3, 37, 38].”
BackgroundDiabetes mellitus and atrial fibrillation-from pathophysiology to treatment
Leopoulou, M., Theofilis, P., Kordalis, A., Παπαγεωργίου, Ν., Sagris, Μ., Oikonomou, E. K., & Tousoulis, D. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.512 · Cited by 53
Catheter ablation of atrial fibrillation in patients with diabetes mellitus
Wang, A., Truong, T., Black‐Maier, E., Green, C. L., Campbell, K. B., Barnett, A. S., Febre, J., Loring, Z., Al‐Khatib, S. M., Atwater, B. D., et al. (2020) · Heart Rhythm O2 · doi:10.1016/j.hroo.2020.04.006 · Cited by 41
“In a population-based cohort study, metformin and thiazolidinediones were associated with decreased risk of incident AF, whereas insulin use was associated with increased risk of incident AF.(19) In a prospective cohort study, pioglitazone was associated with a significantly lower risk of AF recurrence after ablation,…”
BackgroundInfluentialEffects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient
Nantsupawat, T., Wongcharoen, W., Chattipakorn, S. C., & Chattipakorn, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01176-4 · Cited by 42
Lee, T. T. L., Hui, J. M. H., Lee, Y. H. A., Satti, D. I., Shum, Y. K. L., Tang, P., Wai, A. K. C., Liu, T., Wong, W. T., Chan, J. S. K., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026289 · Cited by 43
“5 The effect of antidiabetic medications on atrial fibrillation has been well documented, 6,7 yet not many studies investigated the effect of such medications on the risk of VA/SCD, let alone the comparison between metformin and sulfonylurea use.”
Zhuo, M., D’Andrea, E., Paik, J. M., Wexler, D. J., Everett, B. M., Glynn, R. J., Kim, S. C., & Patorno, E. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.35995 · Cited by 43
Epicardial fat and atrial fibrillation: the perils of atrial failure
Poggi, A. L., Gaborit, B., Schindler, T. H., Liberale, L., Montecucco, F., & Carbone, F. (2022) · EP Europace · doi:10.1093/europace/euac015 · Cited by 46
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101390 · Cited by 36
Hsiao, F., Yen, K., Chao, T., Chen, S., Chan, Y., & Chu, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac402 · Cited by 30
Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation
Özcan, C., Dixit, G., & Li, Z. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10069-6 · Cited by 30
“Metformin was also shown to be associated with decreased risk of AF in patients with diabetes [15, 16].”
BackgroundGlucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus
Fauchier, G., Bisson, A., Bodin, A., Herbert, J., Angoulvant, D., Ducluzeau, P., Lip, G. Y. H., & Fauchier, L. (2021) · Diabetologia · doi:10.1007/s00125-021-05551-y · Cited by 28
“By contrast, in a nested case–control study, use of biguanides or thiazolidinediones was associated with a lower risk of AF, while insulin use was associated with a higher risk of AF [5].”
ResultLee, T.-W., Lee, T.-I., Lin, Y.-K., Chen, Y.-C., Kao, Y.-H., & Chen, Y.-J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03648-y · Cited by 27
Chakraborty, P., Nattel, S., & Nanthakumar, K. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.03.025 · Cited by 27
Atrial Fibrillation and Diabetes Mellitus: Dangerous Liaisons or Innocent Bystanders?
Lorenzo-Almorós, A., Casado, J., Walther, L. A. Á.-S., Méndez‐Bailón, M., & Lorenzo, Ó. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082868 · Cited by 33
Tseng, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.592901 · Cited by 27
“The investigators cross-sectionally estimated the odds ratios of AF for metformin users versus metformin non-users [12].”
BackgroundMethodResultInfluentialManaging thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 28
Lăcătușu, C.-M., Grigorescu, E.-D., Stătescu, C., Sascău, R. A., Onofriescu, A., & Mihai, B. M. (2019) · Medicina · doi:10.3390/medicina55090592 · Cited by 24
“The use of DPP-4 inhibitors was associated with neither an increased nor a decreased risk of new-onset AF in the case-control study on Taiwan registries that was previously mentioned [12].”
BackgroundResultInfluentialFauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P., & Camm, A. J. (2021) · EP Europace · doi:10.1093/europace/euab184 · Cited by 22
Higa, S., Maesato, A., Ishigaki, S., Suenari, K., Chen, Y., & Chen, S. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.11.005 · Cited by 23
Park, C. S., Choi, E., Kyung-DoHan, Yoo, J., Ahn, H., Kwon, S., Lee, S., Oh, S., & Lip, G. Y. H. (2022) · Diabetes Care · doi:10.2337/dc22-1655 · Cited by 21
Raubenheimer, P. J., Cushman, W. C., Avezum, Á., Basile, J., Conget, I., Dagenais, G. R., Hoover, A., Janský, P., Lanas, F. T., Leiter, L. A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14634 · Cited by 18
Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation
Zheng, E., Warchoł, I., Mejza, M., Możdżan, M., Strzemińska, M., Bajer, A., Madura, P., Żak, J., & Plewka, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030882 · Cited by 18
Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies
Grigoriou, K., Karakasis, P., Pamporis, K., Theofilis, P., Patoulias, D., Karagiannidis, E., Fyntanidou, B., Antoniadis, A. P., & Fragakis, N. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070559 · Cited by 18
“More-over, insulin use has been linked to an increased risk of new-onset AF in patients with T2DM, likely due to hypoglycemic episodes that trigger sympathetic activation and the more advanced stage of DM in these individuals [239].”
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
Prídavková, D., Samoš, M., Bolek, T., Škorňová, I., Žolková, J., Kubisz, P., Staško, J., & Mokáň, M. (2019) · Journal of Diabetes Research · doi:10.1155/2019/5158308 · Cited by 17
“On the other hand, several other studies suggested that the risk of incident AF in T2D patients could be reduced with intensive blood pressure lowering therapy [12], biguanides (metformin) and thiazolidinediones [13], or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy [14].”
BackgroundKim, J., Kim, D., Bae, H., Park, B., Kang, T. S., Lim, S., Lee, S. Y., Chung, Y. H., Ryu, J. W., Lee, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02021-0 · Cited by 12
“The duration of diabetes and insulin use are associated with a higher risk of AF and an elevated thromboembolic risk in patients with AF [14, 15, 33, 34].”
BackgroundThe complex interplay between diabetes mellitus and atrial fibrillation
Yildiz, M., Lavie, C. J., Morin, D. P., & Oktay, A. A. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2115357 · Cited by 14
“case-control study from Taiwan reported no relationship between sulfonylureas or insulin and AF risk [114].”
BackgroundAntiarrhythmic effects of metformin
Mascarenhas, L., Downey, M. C., Schwartz, G. G., & Adabağ, S. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.04.003 · Cited by 12
Rafaqat, S., Rafaqat, S., & Rafaqat, S. (2022) · International Journal of Arrhythmia · doi:10.1186/s42444-021-00057-5 · Cited by 12
“[38] reported Pharmacological Treatment Options to treat the patients with severe insulin resistance, such as Biguanides (metformin), thiazolidinediones (TZDs) [Pioglitazone, rosiglitazone], Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Concentrated Insulin Products, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glu…”
BackgroundInfluentialRepurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights
Sarkar, A., Fanous, K., Marei, I., Ding, H., Ladjimi, M. M., MacDonald, R. S., Hollenberg, M. D., Anderson, T. J., Hill, M. A., & Triggle, C. R. (2024) · Vascular Health and Risk Management · doi:10.2147/vhrm.s391808 · Cited by 11
“28 Furthermore, it has not been clearly established whether metformin has CVD protective benefits in patients without diabetes because existing data are controversial, as evident from the Carotid Atherosclerosis: MEtformin for insulin ResistAnce (CAMERA) study.”
BackgroundKantharia, B. K., Tabary, M., Wu, L., Wang, X., Narasimhan, B., Linz, D., Heijman, J., & Wehrens, X. H. T. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16655 · Cited by 11
Packer, M. (2019) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14236 · Cited by 9
Iqbal, A., Tekin, Z., Kattan, M. W., Ji, X., Milinovich, A., Pantalone, K. M., Zimmerman, R. S., Chung, M. K., & Kashyap, S. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108315 · Cited by 9
Thotamgari, S. R., Grewal, U. S., Sheth, A. R., Babbili, A., & Dominic, P. S. (2022) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000265 · Cited by 8
Atrial fibrillation: an underappreciated complication of diabetes
Cai, L., Wan, H., Sun, Y., Middeldorp, M. E., Zhang, Y., Qi, L., Sanders, P., Wang, H., Shi, Y., Zhou, J., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag044 · Cited by 8
Bertrand, A., Tomek, J., & Rodríguez, B. (2026) · The Journal of Physiology · doi:10.1113/jp287140 · Cited by 5
Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
Bourazana, A., Giamouzis, G., Skoularigis, J. S., Triposkiadis, F. K., & Xanthopoulos, A. V. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i4.266 · Cited by 4
Канорский, С. Г., & Kovalenko, Y. S. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-1-19-27 · Cited by 3
Yavuz, Ş., Özsin, K. K., Sanrı, U. S., Toktaş, F., Özsin, M., & Eriş, C. (2022) · Journal of Cardiac Surgery · doi:10.1111/jocs.17028 · Cited by 4
Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici
Marx, N., Federici, M., Schütt, K. S., Müller‐Wieland, D., Ajjan, R., Antunes, M. J., Christodorescu, R., Crawford, C. A., Angelantonio, E. D., Eliasson, B., et al. (2024) · Giornale Ialiano di Cardiologia · doi:10.1714/4162.41558 · Cited by 6
Rodríguez‐Zavala, J. S., & Zazueta, C. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400492 · Cited by 2
Vempati, R., Damarlapally, N., Roy, P., Mylavarapu, M., Vasudevan, S. S., Reguram, R., Vora, T., Jain, H., Ahmed, R., & Krishnamoorthy, G. (2025) · Diagnostics · doi:10.3390/diagnostics15182288 · Cited by 2
“However, Liou et al. [29] reported that, among antihyperglycemic agents, biguanides are linked to the second-lowest risk of new-onset AF in patients with T2DM, following thiazolidinediones.”
Metformin Protects Against Persistent Atrial Fibrillation in an Equine Model
Haugaard, S. L., Schneider, M. J., Kjeldsen, S. T., Sattler, S. M., Bastrup, J., Saljic, A., Birk, J. B., Hansen, C., Synnestvedt, J. N., van Hunnik, A., et al. (2025) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.125.013850 · Cited by 4
Grigore, M., Grigore, A.-M., Ruxandra-Elena, M.-G., Verde, I., Uscoiu, G., Nicolae, C., Balahura, A.-M., & Ilieşiu, A. (2025) · Life · doi:10.3390/life16010016 · Cited by 3
“Beyond their glucose-lowering effects, TZDs exhibit anti-inflammatory and antioxidant properties, which may influence the development of AF [51].”
InfluentialComplex interrelationship and therapeutic advances in diabetic patients with atrial fibrillation
Karanikola, A.-E., Tsiachris, D., Argyriou, N., Botis, M., Pamporis, K., Xydis, P., Fragoulis, C., Kordalis, A., & Tsioufis, K. P. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i12.114575 · Cited by 3
Heo, G. Y., Heo, S., Ko, B., Ko, Y. E., Koh, H. B., Park, C. H., Park, J. T., Han, S. H., Yoo, T.-H., Kang, S., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03024-9 · Cited by 2
“Similarly, although a cohort study suggested that DPP-4 inhibitors were associated with a lower risk of AF [16], larger cohort studies and cardiovascular outcome trials have found no significant association [17, 18].”
Song, H., Kim, Y. R., Lee, S. E., Nam, H., Kim, H., Kyoung, D., & Kim, K. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2309303 · Cited by 2
“Notably, population-based studies showed protective effect of metformin [27] and dipeptidyl peptidase 4 inhibitors [28] and harmful effect of sulfonylurea [29] in terms of new-onset AF.”
BackgroundXie, B., Wang, Z., Lakhani, I., Tse, G., & Liu, T. (2021) · European Journal of Arrhythmia & Electrophysiology · doi:10.17925/ejae.2021.7.1.26 · Cited by 1
“A study examining the effects of insulin, metformin, sulfonylureas, thiazolidinediones and DPP-4 inhibitors, demonstrated that although patients on insulin were more prone to AF development, those on metformin and thiazolidinediones showed a reduction in AF incidence, whereas patients on sulfonylureas and DPP-4 inhibi…”
ResultModern approaches to the treatment of atrial fibrillation in patients with diabetes mellitus.
Serik, S. A., & Strona, V. I. (2022) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2022.01.069 · Cited by 1
Tanaka, A., & Node, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01234-5
“Furthermore, because recent clinical studies have reported substantial differences in the risk of atrial fibrillation between classes of glucose-lowering agents [44, 45], further research is also needed to establish potential or suitable surrogate markers of atrial fibrillation and then examine the effect of each drug…”
BackgroundRodriguez, P. R. T., Fayyaz, F., Deiveegan, D. S., Arif, A., Bukhari, H., Mulaka, G. S. R., Doddareddy, N. P., Ekomwereren, O., Atew, H. G., Mukherjee, S., et al. (2023) · International Journal of Pharmacy and Pharmaceutical Research · doi:10.25166/ijppr.2023.28.2.8
Tüm Yönleri ile AF ve Tedavi Yaklaşımları
Çelik, A., Hakgör, A., Çolak, A., Kunak, A. Ü., Sezenöz, B., Şengör, B. G., Arın, C. B., Coşkun, E. Ç., Ersoy, E. I. Y., Aksakal, E., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1962
AAD in Patients with Comorbidities
Sartiani, L., & Cerbai, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_14
Cardiac arrhythmias and diabetes mellitus: What a clinician needs to know
Nadybina, M. N., Омариевна, У. Ф., & Izmaylova, T. Y. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-05
Song, Z., Zhou, Z., Wang, B., Wu, S., Sun, Y., Chen, Y.-D. I., Feng, S., & Sun, R. (2025) · Journal of Arrhythmia · doi:10.1002/joa3.70241
Chan, Y., Chao, T.-F., Chen, S.-W., Lee, H.-F., Li, P.-R., Chen, W.-M., Yeh, Y., Kuo, C.-T., See, L.-C., & Lip, G. Y. H. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.6084/m9.figshare.20176129
Kim, J., Kim, D., Bae, H.-J., Park, B.-E., Kang, T. S., Lim, S.-H., Lee, S. Y., Chung, Y. H., Ryu, J. W., Lee, M.-Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940482
Chan, Y., Chao, T.-F., Chen, S.-W., Lee, H.-F., Li, P.-R., Chen, W.-M., Yeh, Y., Kuo, C.-T., See, L.-C., & Lip, G. Y. H. (2022) · Figshare · doi:10.6084/m9.figshare.20176126
Chan, Y., Chao, T.-F., Chen, S.-W., Lee, H.-F., Li, P.-R., Chen, W.-M., Yeh, Y., Kuo, C.-T., See, L.-C., & Lip, G. Y. H. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.6084/m9.figshare.20176132
Chan, Y., Chao, T.-F., Chen, S.-W., Lee, H.-F., Li, P.-R., Chen, W.-M., Yeh, Y., Kuo, C.-T., See, L.-C., & Lip, G. Y. H. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.6084/m9.figshare.20176135
Chen, H.-Y., Huang, J., Siao, W.-Z., & Jong, G.-P. (2020) · Figshare · doi:10.6084/m9.figshare.12440942
Self-citationCausal association between metformin and arrhythmias: A Mendelian randomization study
Qin, W., Zhang, J., Zhao, Q., Liu, F., Li, X., & Yang, Y. (2026) · Medicine · doi:10.1097/md.0000000000046091
Atrial Fibrillation in Persons With Type 2 Diabetes
Fauchier, L., & Ducluzeau, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00024-0
ОСОБЕННОСТИ ФАРМАКОТЕРАПИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ
Abbasova, A. F., & Джафарзаде, Ф. Я. (2026) · Успехи геронтологии · doi:10.34922/ae.2025.38.6.014
Vempati, R., Gahona, C. C. T., Haddad, F. F., Manickavelan, H. V., Zakaria, F., Hanna, J., Sanusi, M., Bhatt, P., Haddad, R., Mohammed, F., et al. (2026) · Journal of Molecular Pathology · doi:10.3390/jmp7030025
“Other studies have indicated that metformin users experienced lower hospitalization rates for atrial fibrillation compared to non-users [74,75].”
Ye, X., Wu, Q., Hou, L., Hou, X., Yang, Y., Yang, C., Huang, M., & Wang, S. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70202
“Differentiated risk‐of‐bias assessment tools were adopted according to study design: the Revised Cochrane Risk of Bias Tool (RoB 2) [17] for RCTs and the Risk of Bias in Non‐randomized Studies of Interventions tool (ROBINS‐”
Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation (META-AF)
Deshmukh, A., Shah, M. M., Kozlowski, P., Chakrabarti, A. K., Turin, A., Arps, K. E., Ghannam, M., Liang, J. J., Saeed, M., Cunnane, R. T., et al. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2026.07.008
Metadata
- Authors
- Liou, Y.-S., Yang, F.-Y., Chen, H.-Y., & Jong, G.-P.
- Affiliations
- Taichung Veterans General Hospital (TW)
- China Medical University (TW)
- Chung Shan Medical University Hospital (TW)
- Corresponding author
- Jong, Gwo-Ping
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-08-30
- Volume
- 13
- Issue
- 8
- Pages
- e0197245
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6116917
- OpenAlex
- W2889208017
- Cited by
- 75
- References
- 38
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 20 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 1
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chung Shan Medical University Hospital (2016-012)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- new-onset atrial fibrillation, antidiabetic drugs, type 2 diabetes, biguanides, thiazolidinediones, insulin, sulfonylureas, glinides, alpha-glucosidase inhibitors, DPP-4 inhibitors
- MeSH terms
- Aged, Atrial Fibrillation, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Taiwan, Case-Control Studies, Age of Onset, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.